Your AI-Trained Oncology Knowledge Connection!
EP. 1: Dr Kuykendall on Molecular Testing in Systemic Mastocytosis
Andrew Kuykendall, MD, discusses the importance of testing for mutations in KIT and other genes in patients with systemic mastocytosis.
EP. 2: Dr Kuykendall on AEs With Midostaurin and Avapritinib in Advanced Systemic Mastocytosis
Andrew Kuykendall, MD, discusses the occurrence and management of adverse effects associated with midostaurin and avapritinib in patients with advanced systemic mastocytosis.
EP. 3: Dr Kuykendall on Emerging Therapies in Systemic Mastocytosis
Andrew Kuykendall, MD, discusses agents currently in development for patients with systemic mastocytosis and how these investigational therapies may fit into the overall treatment paradigm for this disease.
EP. 4: Expert Insights on Treatment Selection in Advanced Systemic Mastocytosis
Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia
Axi-Cel, Liso-Cel, and Tisa-Cel Show Comparable Real-World Survival Outcomes in DLBCL
Pirtobrutinib Improves Patient-Reported Outcomes in Relapsed/Refractory CLL/SLL
MAIC Analysis Shows PFS Favorability With Zanubrutinib vs Acalabrutinib/Venetoclax in CLL
